Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy
- 1 March 2007
- Vol. 93 (3), 319-324
- https://doi.org/10.1136/hrt.2006.091751
Abstract
Background: Impaired coronary flow reserve (CFR) is a significant predictor of poor prognosis in patients with idiopathic dilated cardiomyopathy (IDC). Nebivolol reduces mortality and morbidity in patients with heart failure and left ventricular dysfunction, including cases caused by IDC. Objective: To assess the effects of nebivolol on CFR in patients with IDC. Methods: CFR was measured in 21 clinically stable patients with IDC (mean (SD) ejection fraction 35.7 (6.2)) at baseline and after 1 month of treatment with nebivolol once daily. A control group of apparently healthy subjects who were matched for age and sex was used for comparison. Resting and hyperaemic coronary flows were measured using transthoracic second-harmonic Doppler echocardiography. None of the subjects had any systemic disease. Results: After 1 month of treatment, heart rate was reduced significantly (p<0.001). The blood pressure was decreased significantly (p<0.001). The left ventricular end-diastolic diameter and stroke volume were not changed significantly, but end-systolic diameter was decreased significantly (p<0.05). Resting rate–pressure product was lower after treatment with nebivolol, but dipyridamole-induced change was not influenced by the treatment. Nebivolol treatment reduced significantly coronary velocities at rest (p<0.02) and also caused a significant increase in coronary velocities after dipyridamole (p<0.02), leading to a greater CFR (2.02 (0.35) vs 2.61 (0.43), p<0.001). Nebivolol induced an absolute increase of 6% in the CFR in 17 of 21 patients (80.9%). Conclusions: In patients with IDC, 1 month of treatment with nebivolol induces a marked increase in CFR.Keywords
This publication has 23 references indexed in Scilit:
- Coronary flow reserve is preserved in white-coat hypertensionHeart, 2006
- Early recovery of impaired coronary flow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: A serial transthoracic Doppler echocardiographic studyJournal of the American College of Cardiology, 2005
- Third-Generation β-Blockers Stimulate Nitric Oxide Release From Endothelial Cells Through ATP EffluxCirculation, 2003
- Prognostic Role of Myocardial Blood Flow Impairment in Idiopathic Left Ventricular DysfunctionCirculation, 2002
- β-Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA Production and Proliferation of Human Coronary Smooth Muscle and Endothelial CellsJournal of Cardiovascular Pharmacology, 2000
- Vasodilatory capacity of coronary resistance vessels in dilated cardiomyopathyAmerican Heart Journal, 1994
- Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathyJournal of the American College of Cardiology, 1993
- Effect of increases in heart rate and arterial pressure on coronary flow reserve in humansJournal of the American College of Cardiology, 1993
- Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest painJournal of the American College of Cardiology, 1987
- Multifactorial determinants of reduced coronary flow reserve after dipyridamole in dilated cardiomyopathyThe American Journal of Cardiology, 1985